RE:RE:RE:Good to see you back, HH.Agreed - and I really appreciate your prior forward looking post regarding the board requirements for Nasdaq listing (apologies for failing to recall that was your post initially). For as much as they have mentioned Nasdaq, I would certainly hope management has a plan in place to re-shape the board as necessary to enable this...
Realistically, I don't expect a Nasdaq uplisting to occur until after the company has crossed the threshold into actual revenues - so probably at least 5-6 months away at the earliest. I don't really care that much about the exact timing of that (though I certainly think it would be beneficial for market awareness and the stock price - it's coming one way or other eventually regardless. However, I really think DME would stand to benefit greatly from the associated evolution of its board - so I guess that is the real cost of the Nasdaq uplisting likely pushing out. To be clear, that is not a knock on the executives currently sitting on board (in whom I certainly have confidence), nor is it merely a focus on removing Dr. Ward from the picture (as beneficial as that might be) - I have seen first hand many times the enormous benefits that high quality outside directors can bring (in terms of enhanced decision making, strategic vision and planning, operational execution and accountability, and strategic opportunties), and I am anxious for DME to add these key benefits to the team, assets and plan the company currently has in place.